Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.
about
Potential role of a new PEGylated recombinant factor VIII for hemophilia A.Progress and prospects of engineered sequence-specific DNA modulating technologies for the management of liver diseasesFc-fusion technology and recombinant FVIII and FIX in the management of the hemophiliasTherapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia AEvaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotype.Long-Term Safety of PEGylated Coagulation Factor VIII in the Immune-Deficient Rowett Nude Rat.Hemophilia Care in the Pediatric Age.Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in miceClinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.A single chain variant of factor VIII Fc fusion protein retains normal in vivo efficacy but exhibits altered in vitro activity.Regulation of immune responses by the neonatal fc receptor and its therapeutic implicationsDesign of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance.Profile of efraloctocog alfa and its potential in the treatment of hemophilia A.FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes.Issues in assessing products for the treatment of hemophilia - the intersection between efficacy, economics, and ethics.Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia AEfficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports.Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives.The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells.Novel products for haemostasis - current status.Changing paradigm of prophylaxis with longer acting factor concentrates.Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.Longer-acting clotting factor concentrates for hemophilia.Half-life extended factor VIII for the treatment of hemophilia A.A systematic review of definitions and reporting of bleeding outcome measures in haemophilia.New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins.Health-related quality of life assessment in haemophilia patients on prophylaxis therapy: a systematic review of results from prospective clinical trials.Engineering less immunogenic and antigenic FVIII proteins.PK-guided personalized prophylaxis with Nuwiq(®) (human-cl rhFVIII) in adults with severe haemophilia A.BAY 81-8973, a full-length recombinant factor VIII: manufacturing processes and product characteristics.Modulating immunogenicity of factor IX by fusion to an immunoglobulin Fc domain: a study using a hemophilia B mouse model.Half-life extended biotherapeutics.Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A.Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq(®) ) in adults with severe haemophilia A: efficacy and safety.Haemophilia treatment in 2030.The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.Long-term efficacy and safety of prophylaxis with recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study.
P2860
Q26744309-80A2A286-21EB-4F51-A272-13F955564055Q27011249-3C88A897-2A1A-42EE-A147-A0999CB46588Q27014771-184DA638-827F-4DB4-BD6E-BE1C27F93071Q28075081-705ED7DA-5956-4FB1-BA13-FE075C2DEC44Q30491639-BC3D19FE-39C5-4EEE-9C4E-2063C8428B1BQ33552218-82CA78F4-FC12-43C1-AF2F-DADE20B3245EQ33737259-E178C2B6-CEEC-4D97-8656-5A580E7F9EC4Q33820925-4036A390-4CEF-4039-97A9-D8047E7BB213Q33917215-99B585E5-2552-44B5-B36A-5112CD559CEBQ34045763-B7EDDE6D-35E9-427C-B33F-95A7AF9E93CBQ34503723-9B9218FB-D0CF-461E-8801-FF66789828A1Q34557556-689E305C-C1AB-4BDE-BF8A-39955EE76B33Q34818194-A0AA5555-3C08-40DE-97CD-B71D49AF9877Q35168244-6EBE80BF-7BE5-4475-8ACD-BE2C35BB2CD4Q35565320-58AA892E-F4A0-4C1E-A173-3D85CF1159E2Q35612397-190111BC-A242-48FC-B6B2-4B280A7C9A10Q35766551-BF73B48D-68E4-4EE8-9427-32471268043CQ36000862-D64AC112-D051-4046-8CDD-00D9EEF98079Q37153245-069E896F-645C-4EA4-AFAF-4B76E582726FQ37320598-00162FD5-BE71-4FA3-83F2-CCB165DFC66BQ37494846-F7F8F4DA-E8AA-4BF2-B5FE-2719BBF542CEQ37618821-E1492E93-139C-4272-9F65-26A862689260Q38206849-2B0245BF-E2E0-4CE7-8844-BD3B1D374C5EQ38206858-B01A1080-D4EA-4F78-B5BC-0EBB7200DCDEQ38371071-B331F339-3D5E-4DC1-AC6A-D8DCBAFA97B9Q38543283-DEB9A66F-C0EB-4756-AE89-8984025F3C4BQ38543286-80962FF7-52CD-42F1-9333-3279C237AD82Q38548021-B62862F5-C6CF-40A8-A996-7ED1872890DBQ38574414-B0BC541F-C208-414E-A77D-8A4C4BC8DE61Q38590269-2EB6F429-C094-4D00-9A68-02457277D68CQ38632876-55B7C805-687C-48E1-9060-131BD260B153Q38705742-3BF5560B-256B-4D18-9222-13F61528D195Q38725317-CAEDBAE2-6717-4F0C-BAD2-E8A28E2F01C9Q38760836-CA048AD2-01F7-480A-8D08-203A2B952B21Q38770067-E64744AE-001F-4FCB-817B-CEC43307E167Q38828174-AFAD76BC-15B7-4BC8-B636-70977DA3D44AQ38840145-400BD1D6-F371-4870-8644-593172291B52Q38842671-FDCDC87E-FE36-43CB-88E6-5A8DA33E0B6EQ38867485-AA45FB95-6C1B-44A7-A562-7FA824621D43Q38888065-3253EA50-DC8B-449A-B9E1-6F2AE935110A
P2860
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.
@en
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.
@nl
type
label
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.
@en
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.
@nl
prefLabel
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.
@en
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.
@nl
P2093
P2860
P921
P1433
P1476
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.
@en
P2093
A-LONG Investigators
Amy Shapiro
Aoife Brennan
David Perry
Glenn F Pierce
Gloria Vigliani
Haiyan Jiang
Hideji Hanabusa
Ivan Nestorov
P2860
P304
P356
10.1182/BLOOD-2013-10-529974
P407
P577
2013-11-13T00:00:00Z